Exhibit 99.1 News Release Abbott Reports Second-Quarter 2025 Results – Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales 1 – Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 – Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase – Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase ABBOTT PARK, Ill., July 17, 2025 — Abbott today announced financial results for the second quarter ended June 30, 2025. • Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales 1 . • Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year. • First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales 2 . • Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. • Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint. • In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex ™ Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib). • In April, Abbott announced late-breaking data from the AVEIR ™ Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms. • In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne ™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease. • Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028. "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026." Page 1 of 20 SECOND-QUARTER BUSINESS OVERVIEW Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect ® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Second Quarter 2025 Results (2Q25) Sales 2Q25 ($ in millions) Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices U.S. 4,276 957 811 — 2,503 International 6,866 1,255 1,362 1,383 2,866 Total reported 11,142 2,212 2,173 1,383 5,369 % Change vs. 2Q24 U.S. 8.7 2.6 (0.1) n/a 14.6 International 6.6 3.1 (1.5) 6.9 12.4 Total reported 7.4 2.9 (1.0) 6.9 13.4 Impact of foreign exchange 0.5 (0.5) 0.4 (0.8) 1.2 Organic 6.9 3.4 (1.4) 7.7 12.2 Impact of COVID-19 testing sales 1 (0.6) — (2.2) — — Organic (excluding COVID-19 tests) 7.5 3.4 0.8 7.7 12.2 Organic U.S. 8.7 2.6 (0.1) n/a 14.6 International 5.8 4.0 (2.2) 7.7 10.1 First Half 2025 Results (1H25) Sales 1H25 ($ in millions) Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices U.S. 8,444 1,912 1,682 — 4,842 International 13,056 2,446 2,545 2,643 5,422 Total reported 21,500 4,358 4,227 2,643 10,264 % Change vs. 1H24 U.S. 8.5 5.6 (3.5) n/a 14.8 International 3.9 1.6 (4.5) 4.9 9.1 Total reported 5.7 3.3 (4.1) 4.9 11.7 Impact of foreign exchange (1.1) (1.5) (0.9) (2.9) (0.7) Impact of business exit* (0.1) (0.3) — — — Organic 6.9 5.1 (3.2) 7.8 12.4 Impact of COVID-19 testing sales 2 (1.0) — (3.9) — — Organic (excluding COVID-19 tests) 7.9 5.1 0.7 7.8 12.4 Organic U.S. 8.7 6.4 (3.5) n/a 14.8 International 5.8 4.1 (3.0) 7.8 10.3 R efer to page 16 fo r a reconciliation of adjusted historical revenue to reported revenue. *Re flects the impact of discontinuing the ZonePerfect ® product line in the Nutrition business in March 2024. Page 2 of 20 Nutrition Second Quarter 2025 Results (2Q25) Sales 2Q25 ($ in millions) Total Pediatric Adult U.S. 957 587 370 International 1,255 467 788 Total reported 2,212 1,054 1,158 % Change vs. 2Q24 U.S. 2.6 4.2 0.2 International 3.1 (5.7) 9.2 Total reported 2.9 (0.4) 6.1 Impact of foreign exchange (0.5) (0.6) (0.5) Organic 3.4 0.2 6.6 U.S. 2.6 4.2 0.2 International 4.0 (4.5) 9.8 Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter. Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure ® , Abbott's market-leading complete and balanced nutrition brand, and Glucerna ® , Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes. First Half 2025 Results (1H25) Sales 1H25 ($ in millions) Total Pediatric Adult U.S. 1,912 1,175 737 International 2,446 920 1,526 Total reported 4,358 2,095 2,263 % Change vs. 1H24 U.S. 5.6 9.0 0.6 International 1.6 (7.0) 7.7 Total reported 3.3 1.3 5.3 Impact of foreign exchange (1.5) (1.2) (1.6) Impact of business exit* (0.3) — (0.7) Organic 5.1 2.5 7.6 U.S. 6.4 9.0 2.4 International 4.1 (4.6) 10.2 *R e flects the impact of discontinuing the ZonePerfect ® product line in the Nutrition business in March 2024. Page 3 of 20 Diagnostics Second Quarter 2025 Results (2Q25) Sales 2Q25 ($ in millions) Total Core Laboratory Molecular Point of Care Rapid Diagnostics U.S. 811 351 35 104 321 International 1,362 1,007 88 44 223 Total reported 2,173 1,358 123 148 544 % Change vs. 2Q24 U.S. (0.1) 7.3 5.5 (2.0) (7.1) International (1.5) 0.5 (5.6) (11.9) (6.1) Total reported (1.0) 2.2 (2.7) (5.1) (6.7) Impact of foreign exchange 0.4 0.6 0.7 0.1 0.1 Organic (1.4) 1.6 (3.4) (5.2) (6.8) U.S. (0.1) 7.3 5.5 (2.0) (7.1) International (2.2) (0.3) (6.5) (12.1) (6.3) Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales 1 . Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year. Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China. First Half 2025 Results (1H25) Sales 1H25 ($ in millions) Total Core Laboratory Molecular Point of Care Rapid Diagnostics U.S. 1,682 683 75 204 720 International 2,545 1,852 170 86 437 Total reported 4,227 2,535 245 290 1,157 % Change vs. 1H24 U.S. (3.5) 7.2 — (0.3) (12.8) International (4.5) (2.4) (6.1) (4.5) (12.3) Total reported (4.1) 0.1 (4.4) (1.6) (12.6) Impact of foreign exchange (0.9) (1.2) (1.0) (0.4) (0.6) Organic (3.2) 1.3 (3.4) (1.2) (12.0) U.S. (3.5) 7.2 — (0.3) (12.8) International (3.0) (0.7) (4.9) (3.3) (10.7) Page 4 of 20 Established Pharmaceuticals Second Quarter 2025 Results (2Q25) Sales 2Q25 ($ in millions) Total Key Emerging Markets Other U.S. — — — International 1,383 1,059 324 Total reported 1,383 1,059 324 % Change vs. 2Q24 U.S. n/a n/a n/a International 6.9 7.3 5.9 Total reported 6.9 7.3 5.9 Impact of foreign exchange (0.8) (1.4) 1.4 Organic 7.7 8.7 4.5 U.S. n/a n/a n/a International 7.7 8.7 4.5 Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter. Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East. First Half 2025 Results (1H25) Sales 1H25 ($ in millions) Total Key Emerging Markets Other U.S. — — — International 2,643 2,024 619 Total reported 2,643 2,024 619 % Change vs. 1H24 U.S. n/a n/a n/a International 4.9 5.7 2.4 Total reported 4.9 5.7 2.4 Impact of foreign exchange (2.9) (3.3) (1.4) Organic 7.8 9.0 3.8 U.S. n/a n/a n/a International 7.8 9.0 3.8 Page 5 of 20 Medical Devices Second Quarter 2025 Results (2Q25) Sales 2Q25 ($ in millions) Total Rhythm Management Electro- physiology Heart Failure Vascular Structural Heart Neuro-modulation Diabetes Care U.S. 2,503 340 322 282 283 289 193 794 International 2,866 333 378 86 474 347 61 1,187 Total reported 5,369 673 700 368 757 636 254 1,981 % Change vs. 2Q24 U.S. 14.6 16.5 12.2 15.8 3.0 12.2 0.4 24.5 International 12.4 5.7 10.9 11.2 5.4 13.7 20.4 17.5 Total reported 13.4 10.9 11.5 14.7 4.5 13.0 4.6 20.2 Impact of foreign exchange 1.2 1.1 1.2 0.7 1.0 1.3 0.3 1.7 Organic 12.2 9.8 10.3 14.0 3.5 11.7 4.3 18.5 U.S. 14.6 16.5 12.2 15.8 3.0 12.2 0.4 24.5 International 10.1 3.6 8.8 8.4 3.8 11.4 18.7 14.7 Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre ® , Navitor ® , TriClip ® and AVEIR ® . In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis. First Half 2025 Results (1H25) Sales 1H25 ($ in millions) Total Rhythm Management Electro- physiology Heart Failure Vascular Structural Heart Neuro-modulation Diabetes Care U.S. 4,842 644 621 544 551 571 369 1,542 International 5,422 614 708 163 916 642 113 2,266 Total reported 10,264 1,258 1,329 707 1,467 1,213 482 3,808 % Change vs. 1H24 U.S. 14.8 14.4 11.7 13.2 4.2 16.3 (1.1) 25.7 International 9.1 1.2 7.6 12.6 3.5 9.3 18.5 13.8 Total reported 11.7 7.6 9.5 13.1 3.8 12.5 2.9 18.4 Impact of foreign exchange (0.7) (0.4) (0.6) (0.2) (0.7) (0.7) (0.4) (0.7) Organic 12.4 8.0 10.1 13.3 4.5 13.2 3.3 19.1 U.S. 14.8 14.4 11.7 13.2 4.2 16.3 (1.1) 25.7 International 10.3 2.0 8.8 13.4 4.8 10.5 20.5 15.0 Page 6 of 20 ABBOTT'S FINANCIAL GUIDANCE Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. ABBOTT DECLARES 406 th CONSECUTIVE QUARTERLY DIVIDEND On June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn , Facebook , Instagram , X and YouTube. Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. Page 7 of 20 — Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Abbott Financial: Michael Comilla, 224-668-1872 Tamika McLoughlin, 224-399-5082 Randy Blakley, 224-361-7966 Abbott Media: Karen Twigg May, 224-668-2681 Kate Dyer, 224-668-9965 1. In the second quarter of 2025, total worldwide sales were $11.142 billion, total Diagnostics sales were $2.173 billion and COVID-19 testing-related sales were $55 million. In the second quarter of 2024, total worldwide sales were $10.377 billion, total Diagnostics sales were $2.195 billion and COVID-19 testing-related sales were $102 million. 2. In the first half of 2025, total worldwide sales were $21.500 billion, total Diagnostics sales were $4.227 billion and COVID-19 testing-related sales were $139 million. In the first half of 2024, total worldwide sales were $20.341 billion, total Diagnostics sales were $4.409 billion and COVID-19 testing-related sales were $306 million. Page 8 of 20 Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q25 2Q24 % Change Net Sales $11,142 $10,377 7.4 Cost of products sold, excluding amortization expense 4,854 4,603 5.5 Amortization of intangible assets 420 471 (10.7) Research and development 725 698 3.9 Selling, general, and administrative 3,091 2,936 5.3 Total Operating Cost and Expenses 9,090 8,708 4.4 Operating Earnings 2,052 1,669 23.0 Interest expense, net 50 58 (14.2) Net foreign exchange (gain) loss (11) (6) 55.6 Other (income) expense, net (137) 10 n/m Earnings before taxes 2,150 1,607 33.8 Taxes on earnings 371 305 21.3 1) Net Earnings $1,779 $1,302 36.7 Net Earnings excluding Specified Items, as described below $2,213 $2,003 10.5 2) Diluted Earnings per Common Share $1.01 $0.74 36.5 Diluted Earnings per Common Share, excluding Specified Items, as described below $1.26 $1.14 10.5 2) Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,751 1,751 NOTES: See tables on page 13 for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following page. Page 9 of 20 1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses. 2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Page 10 of 20 Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H25 1H24 % Change Net Sales $21,500 $20,341 5.7 Cost of products sold, excluding amortization expense 9,322 9,066 2.8 Amortization of intangible assets 840 943 (10.8) Research and development 1,441 1,382 4.3 Selling, general, and administrative 6,152 5,895 4.4 Total Operating Cost and Expenses 17,755 17,286 2.7 Operating Earnings 3,745 3,055 22.6 Interest expense, net 99 119 (16.4) Net foreign exchange (gain) loss (18) (6) n/m Other (income) expense, net (264) (101) n/m Earnings before taxes 3,928 3,043 29.1 Taxes on earnings 824 516 59.5 1) Net Earnings $3,104 $2,527 22.9 Net Earnings excluding Specified Items, as described below $4,132 $3,732 10.7 2) Diluted Earnings per Common Share $1.77 $1.44 22.9 Diluted Earnings per Common Share, excluding Specified Items, as described below $2.35 $2.12 10.8 2) Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,749 1,750 NOTES: See tables on page 14 for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following page. Page 11 of 20 1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses. 2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Page 12 of 20 Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q25 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 420 $ (420) $ — Gross Margin 5,868 478 6,346 R&D 725 (20) 705 SG&A 3,091 (1) 3,090 Other (income) expense, net (137) (1) (138) Earnings before taxes 2,150 500 2,650 Taxes on Earnings 371 66 437 Net Earnings 1,779 434 2,213 Diluted Earnings per Share $ 1.01 $ 0.25 $ 1.26 Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 17 for additional details regarding specified items. 2Q24 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 471 $ (471) $ — Gross Margin 5,303 506 5,809 R&D 698 (41) 657 SG&A 2,936 (57) 2,879 Other (income) expense, net 10 (145) (135) Earnings before taxes 1,607 749 2,356 Taxes on Earnings 305 48 353 Net Earnings 1,302 701 2,003 Diluted Earnings per Share $ 0.74 $ 0.40 $ 1.14 Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 18 for additional details regarding specified items. Page 13 of 20 Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H25 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 840 $ (840) $ — Gross Margin 11,338 926 12,264 R&D 1,441 (47) 1,394 SG&A 6,152 (11) 6,141 Other (income) expense, net (264) (36) (300) Earnings before taxes 3,928 1,020 4,948 Taxes on Earnings 824 (8) 816 Net Earnings 3,104 1,028 4,132 Diluted Earnings per Share $ 1.77 $ 0.58 $ 2.35 Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 19 for additional details regarding specified items. 1H24 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 943 $ (943) $ — Gross Margin 10,332 1,024 11,356 R&D 1,382 (62) 1,320 SG&A 5,895 (91) 5,804 Other (income) expense, net (101) (171) (272) Earnings before taxes 3,043 1,348 4,391 Taxes on Earnings 516 143 659 Net Earnings 2,527 1,205 3,732 Diluted Earnings per Share $ 1.44 $ 0.68 $ 2.12 Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 20 for additional details regarding specified items. Page 14 of 20 A reconciliation of the second-quarter tax rates for 2025 and 2024 is shown below: 2Q25 ($ in millions) Pre-Tax Income Taxes on Earnings Tax Rate As reported (GAAP) $ 2,150 $ 371 17.3 % 1) Specified items 500 66 Excluding specified items $ 2,650 $ 437 16.5 % 2Q24 ($ in millions) Pre-Tax Income Taxes on Earnings Tax Rate As reported (GAAP) $ 1,607 $ 305 19.0 % 2) Specified items 749 48 Excluding specified items $ 2,356 $ 353 15.0 % 1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2) 2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below: 1H25 ($ in millions) Pre-Tax Income Taxes on Earnings Tax Rate As reported (GAAP) $ 3,928 $ 824 21.0 % 3) Specified items 1,020 (8) Excluding specified items $ 4,948 $ 816 16.5 % 1H24 ($ in millions) Pre-Tax Income Taxes on Earnings Tax Rate As reported (GAAP) $ 3,043 $ 516 17.0 % 4) Specified items 1,348 143 Excluding specified items $ 4,391 $ 659 15.0 % 3) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 4) 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. Page 15 of 20 Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Half Ended June 30, 2025 and 2024 ($ in millions) (unaudited) 1H25 1H24 % Change vs. 1H24 Non-GAAP Abbott Reported Abbott Reported Impact from business exit (a) Adjusted Revenue Reported Adjusted Organic Total Company 21,500 20,341 (13) 20,328 5.7 5.8 6.9 U.S. 8,444 7,780 (13) 7,767 8.5 8.7 8.7 Intl 13,056 12,561 — 12,561 3.9 3.9 5.8 Total Nutrition 4,358 4,218 (13) 4,205 3.3 3.6 5.1 U.S. 1,912 1,811 (13) 1,798 5.6 6.4 6.4 Intl 2,446 2,407 — 2,407 1.6 1.6 4.1 Adult Nutrition 2,263 2,150 (13) 2,137 5.3 6.0 7.6 U.S. 737 733 (13) 720 0.6 2.4 2.4 Intl 1,526 1,417 — 1,417 7.7 7.7 10.2 (a) R e flects the impact of discontinuing the ZonePerfect ® product line in the Nutrition business in March 2024. Page 16 of 20 Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds Gross Margin $ 1 $ 55 $ 420 $ 2 $ 478 R&D — (7) — (13) (20) SG&A (3) 1 — 1 (1) Other (income) expense, net (1) — — — (1) Earnings before taxes $ 5 $ 61 $ 420 $ 14 500 Taxes on Earnings (d) 66 Net Earnings $ 434 Diluted Earnings per Share $ 0.25 The table above provides additional details regarding the specified items described on page 13. a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products. d) Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 17 of 20 Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds Gross Margin $ 1 $ 32 $ 471 $ 2 $ 506 R&D (1) 1 — (41) (41) SG&A (11) (10) — (36) (57) Other (income) expense, net (147) — — 2 (145) Earnings before taxes $ 160 $ 41 $ 471 $ 77 749 Taxes on Earnings (d) 48 Net Earnings $ 701 Diluted Earnings per Share $ 0.40 The table above provides additional details regarding the specified items described on page 13 . a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR requirements for previously approved products and an intangible asset impairment charge. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. Page 18 of 20 Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds Gross Margin $ 1 $ 81 $ 840 $ 4 $ 926 R&D (1) (23) — (23) (47) SG&A (6) (6) — 1 (11) Other (income) expense, net (25) — — (11) (36) Earnings before taxes $ 33 $ 110 $ 840 $ 37 1,020 Taxes on Earnings (d) (8) Net Earnings $ 1,028 Diluted Earnings per Share $ 0.58 The table above provides additional details regarding the specified items described on page 14. a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments. d) Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 19 of 20 Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds Gross Margin $ 2 $ 74 $ 943 $ 5 $ 1,024 R&D (4) (1) — (57) (62) SG&A (25) (19) — (47) (91) Other (income) expense, net (135) — — (36) (171) Earnings before taxes $ 166 $ 94 $ 943 $ 145 1,348 Taxes on Earnings (d) 143 Net Earnings $ 1,205 Diluted Earnings per Share $ 0.68 The table above provides additional details regarding the specified items described on page 14. a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. Page 20 of 20

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.